Chemotherapy Agents
Chemotherapy Agents - Related Videos
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
0 Views •
Cited by 28 •
2012
This abstract describes a novel method to assess the development of neurotoxicity in patients receiving chemotherapy treatment. While conventional assessment methods are limited in their ability to detect early changes in nerve function, nerve excitability techniques provide early identification of patients at risk of severe neurotoxicity and insight into pathophysiology.
08:41
Modeling Chemotherapy Resistant Leukemia In Vitro
0 Views •
Cited by 15 •
2016
The current report summarizes a protocol that can be utilized to model the influence of the bone marrow microenvironment niche on leukemic cells with emphasis placed on enrichment of the most chemoresistant subpopulation.
11:27
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
0 Views •
Cited by 5 •
2016
This protocol describes the preparation and characterization of a dendrimeric magnetic resonance imaging (MRI) contrast agent that carries cyclen-based macrocyclic chelates coordinating paramagnetic gadolinium ions. In a series of MRI experiments in vitro, this agent produced an amplified MRI signal when compared to the commercially available monomeric analogue.
10:19
Reducing Agents
0 Views •
2023
Source: Vy M. Dong and Daniel Kim, Department of Chemistry, University of California, Irvine, CA Controlling the reactivity and selectivity during the synthesis of a molecule is very important criteria for chemists. This has led to the development of many reagents that allow chemists to pick and choose reagents suitable for a given task. Quite often, a balance between reactivity and selectivity needs to be achieved. This experiment will use IR spectroscopy to monitor the reaction and to...
05:06
Alkaline Single Cell Gel Electrophoresis: A Sensitive Technique for Quantitative Estimation of DNA Damage in Individual Cancer Cells Following Chemotherapy
0 Views •
2025
In this video, we demonstrate an alkaline single-cell electrophoresis assay to quantify both single- and double-strand DNA breaks in doxorubicin-treated cells. Alkaline conditions disrupt the hydrogen bonds between DNA base pairs, resulting in the complete unwinding and separation of DNA strands. This allows differential migration of undamaged and damaged DNA fragments in agarose gel upon electrophoresis, revealing a comet-shaped structure of slowly migrating undamaged DNA forming the circular...
FAQs
Different classes attack essential cellular processes in distinct ways. Some damage DNA directly, while others prevent DNA or RNA synthesis, interrupt cell division, or disrupt metabolic pathways needed for growth. These mechanisms can produce different effects across tumors, so treatment planning considers which cellular vulnerabilities are most relevant to the malignancy being treated.
The lack of perfect selectivity explains many treatment-related effects. Chemotherapy agents often act most strongly on rapidly dividing cells, a feature shared by many cancers and by normal tissues such as bone marrow and the intestinal lining. Damage to these healthy tissues can accompany antitumor activity and influences how clinicians plan treatment.
Combinations allow clinicians to target malignant disease through more than one cellular mechanism. One medicine may damage DNA, another may block nucleic-acid synthesis, and another may interfere with cell division or metabolism. The overview indicates that such choices depend on tumor type, stage, molecular features, and treatment goals rather than on a universal regimen.
Treatment selection integrates several characteristics of the disease. Tumor type identifies the malignancy being treated, stage indicates how advanced it is, and molecular features provide additional information about the tumor. Clinicians also weigh whether the goal is cure, reducing tumor burden before surgery, controlling advanced disease, or relieving symptoms.
Chemotherapy may be used before surgery to reduce tumor burden. This approach places the medicines within a broader treatment plan rather than using them as an isolated intervention. The decision depends on the cancer’s type, stage, molecular features, and the intended treatment goal, with the preoperative objective focused on making the disease less extensive before an operation.
For advanced disease, chemotherapy can serve goals other than cure. Clinicians may use it to control the malignancy or relieve symptoms, depending on the patient’s disease characteristics and treatment objectives. This distinction helps explain why the same broad class of medicines may be incorporated into different plans, including disease control or symptom-focused care.